<DOC>
	<DOCNO>NCT00334412</DOCNO>
	<brief_summary>Combination therapy caspofungin amphotericin B could useful treatment option invasive fungal disease , routinely recommend ; carefully control well-designed randomized clinical trial need .</brief_summary>
	<brief_title>COMBISTRAT : AmBisome® Combination With Caspofungin Treatment Invasive Aspergillosis</brief_title>
	<detailed_description>Efficacy toxicity caspofungin combination AmBisome® primary salvage treatment invasive aspergillosis already assess patient hematologic malignancy . Forty-eight patient document ( n=23 ) possible ( n=25 ) Invasive Aspergillosis ( IA ) . The majority patient ( 65 % ) receive combination salvage therapy progressive IA despite 7 day previous AmBisome monotherapy . The overall response rate 42 % . No significant toxic effect see . Factors associate failure end therapy document IA ( P=0.03 ) , significant steroid use study ( P=0.02 ) , duration combination therapy le 14 day ( P=0.01 ) . The response rate patient progressive document IA low ( 18 % ) . Authors ' conclude combination promise therapy IA generally well tolerated.35 Furthermore interaction caspofungin amphotericin B clinical isolates Aspergillus Fusarium assess . Antagonism observe isolates test . Caspofungin amphotericin B synergistic synergistic additive least half isolates studied.36 Gentina et al . evaluate , refractory IA , i.v . antifungal therapy combine caspofungin ( 70 mg D1 , follow 50 mg/d ) Vfend® ( 200 mg b.i.d ) AmBisome ( 5 mg/kg/d ) . Six leukaemia patient refractory IA receive combination include caspofungin AmBisome ( n = 4 ) Vfend ( n = 2 ) . Combination therapy start 8 day initial IA diagnosis . Duration neutropenia initiation combination therapy range 4 25 day . IA classify definite 3 case probable 3 case . All patient pulmonary IA , include one disseminate IA ( cerebral , thyroid , ocular pulmonary ) . In patient , sequential CT-scans demonstrated improvement rapid reduction size lesion . Additional surgery require 2 case . Improvement allow administration consolidation chemotherapy 3 patient without recurrence IA . Median duration combination therapy 62 day ( range 42-107 ) . No toxicity relate combination antifungal therapy observed.37 The combination therapy caspofungin amphotericin ( liposomal amphotericin ) also assess Aliff et al . retrospective evaluation group 30 patient amphotericin-resistant pulmonary aspergillosis invasive fungal infection . Twenty-six patient acute leukemia . Diagnosis base clinical , radiographic , available , microbiologic data . Response combination antifungal therapy grade either favorable unfavorable . Favorable response include improvement clinical radiographic sign fungal pneumonia . All response grade unfavorable . Based EORTC criterion , IFIs classify proven 6 patient , probable 4 patient , possible 20 patient . The median duration dose amphotericin monotherapy 12 day ( range , 4-65 day ) 7.8 mg/kg ( range , 4.2-66.1 mg/kg ) , respectively . The median duration combination therapy 24 day ( range , 3-74 day ) . Eighteen patient ( 60 % ) experience favorable antifungal response . Twenty patient acute leukemia receive combination therapy fungal pneumonia arise intensive chemotherapy treatment . Favorable response observe 15 patient ( 75 % ) , antifungal response depend response underlie leukemia . Survival hospital discharge significantly well ( P &lt; 0.001 ) patient favorable response . Authors conclude combination caspofungin amphotericin B administer safely high-risk patient hematologic malignancies.38 Combination therapy could useful treatment option invasive fungal disease , routinely recommend ; carefully control well-designed randomized clinical trial need .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<criteria>Adults child &gt; 10 year old . The patient able understand sign write informed consent OR parent legal guardian able understand sign write informed consent , must obtain prior initiation study procedure . Immunocompromised due hematologic malignancy , chemotherapyinduced neutropenia , solid organ transplantation , condition result severe neutropenia , HIV infection , prolong corticosteroid therapy ( ≥ 20 mg Prednisone equivalent ≥ 3 week ) treatment immunosuppressant medication . Evidence Proven Probable Invasive Aspergillosis , modify EORTC criterion ( Appendix 2 ) , modify : • Proven Invasive Aspergillosis • Histopathologic cytopathologic examination show hyphae consistent presence aspergillus needle aspiration biopsy specimen evidence associate tissue damage ( either microscopically unequivocally image ) ; • Positive culture result aspergillosis sample obtain sterile procedure normally sterile clinically radiologically abnormal site consistent infection , exclude urine mucous membrane • Probable Invasive Aspergillosis • At least 1 host factor criterion ; • 1 microbiological criterion ; 1 major ( 2 minor ) clinical criterion abnormal site consistent infection ; • No pathogen detect account clinical radiographic sign infection Or ( Modification EORTC Criteria ) : • Patients recent Neutropenia ( absolute neutrophil count &lt; 500 cells/mm3 within 14 day study enrollment ) ; • Chest CT scan positive `` Halo '' `` Air Crescent '' Sign ( see Section 4.2.1 , Diagnostic Considerations , ) • No pathogen detect account clinical radiographic sign infection Females childbearing potential must surgically incapable pregnancy , practice acceptable method birth control negative pregnancy test ( blood urine ) baseline . Life expectancy &lt; 30 day Allogenic stem cell transplant 6 previous month Chronic invasive fungal infection , define signs/symptoms invasive fungal infection present &gt; 4 week precede entry study Prior antifungal systemic therapy ≥ 96 hour current , documented IA . ( On hand , permissible prior systemic antifungal therapy prophylaxis empiric therapy febrile neutropenia ) . Use another investigational , unlicensed drug within 30 day screen concurrent participation another clinical trial use investigational , unlicensed drug • Serum creatinine &gt; 2x upper limit normal ( ULN ) Serum ALT AST &gt; 5 x ULN Pregnant lactate woman History allergy serious adverse reaction polyene antifungal agent echinochandin derivative</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>